NIDDK Archives
Diabetes, cardiovascular drug targets
May. 24, 2022—Targeting receptors of the inflammatory lipid signaling molecule PGE2 may offer a new way to tackle both Type 2 diabetes and cardiovascular disease, Vanderbilt researchers have discovered.
Genetics and blood pressure
May. 19, 2022—Including polygenic risk scores for blood pressure may improve predictive models to identify people at risk for treatment-resistant hypertension.
Reducing obesity-related inflammation
Mar. 24, 2022—A treatment that increases levels of lipid signaling molecules reduced adipose tissue inflammation in obese adults, suggesting this pathway may be a valuable target for modulating fat and systemic inflammation.
Diverticulitis surgery: guidelines needed
Feb. 10, 2022—Surgical removal of the colon for recurrent diverticulosis varies by geographic region and is associated with surgeon and hospital factors; stronger national guidelines are needed, Vanderbilt researchers report.
New insights into hypothalamic obesity
Feb. 10, 2022—A common Type 2 diabetes treatment being tested for hypothalamic obesity had unexpected results on weight loss and total energy expenditure, Vanderbilt researchers report.
Impact of digital health interventions
Jan. 31, 2022—Vanderbilt researchers test and recommend statistical approaches to study the association between engagement with digital health interventions and clinical outcomes.
Impaired neutrophils in autoimmunity
Jan. 27, 2022—Vanderbilt researchers help answer the question of why patients with autoimmune diseases like lupus are more susceptible to bacterial infections: their neutrophils have impaired antibacterial activity.
The role of integrins in kidney “integrity”
Jan. 13, 2022—Receptors called integrins play a critical role in maintaining the structure of the kidney, Vanderbilt researchers have discovered.
Salmonella overcomes host resistance
Jan. 13, 2022—The invading pathogen Salmonella, a common cause of food poisoning, can change its metabolism to overcome host resistance to its colonization.
CRISPR screen identifies new anti-inflammatory drug target
Nov. 11, 2021—A novel CRISPR screen developed by Vanderbilt researchers identified a promising new target for anti-inflammatory therapeutics.
New way to bEET insulin resistance
Nov. 11, 2021—Signaling molecules called EETs could improve insulin resistance, a primary risk factor for Type 2 diabetes and cardiovascular disease, Vanderbilt researchers have discovered.
Harrison Society researcher discovers key regulator of kidney cell structure
Nov. 4, 2021—New research from Vanderbilt could aid efforts to promote kidney regeneration after injury or to develop engineered organs.
